New Delhi-based Glenmark's USFDA-approved 15 mg and 25 mg Topiramate capsules, equivalent to Janssen's Topamax, will be marketed by Glenmark Pharmaceuticals Inc., USA. Topamax had recorded annual sales worth USD 21.9 million per IQVIATM (till May 2024). Glenmark's US portfolio has 198 products, 50 ANDAs pending, and seeks growth through external development partnerships.
